Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReCLAIM: Elamipretide in Intermediate AMD
NCT02848313Phase 1Completed
- Sponsor
- Stealth BioTherapeutics
- Start
- Oct 2016
- Primary completion
- Mar 2018
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of elamipretide in age-related macular degeneration (AMD) (2 arms), sponsored by Stealth BioTherapeutics. Primary endpoints: Safety and Tolerability at 12 weeks and Best-corrected Visual Acuity (Standard Luminance) at 28 weeks. Started Oct 2016; status: completed.
02
Drugs
elamipretide
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT02848313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02848313.